多柔比星脂质体一线用于老年淋巴瘤患者的临床疗效及安全性

Clinical efficacy and safety of the first line of doxorubicin liposome(PLD) in elderly patients with lymphoma

目的:探讨含多柔比星脂质体(PLD)的化疗方案一线用于老年淋巴瘤患者的疗效及安全性。方法:收治>65岁老年淋巴瘤患者68例,接受含PLD的化疗方案者38例,其中弥漫大B细胞淋巴瘤17例,滤泡型淋巴瘤7例,套细胞淋巴瘤6例,T细胞淋巴瘤5例。其他3例。结果:骨髓毒性是最常出现的不良反应,无患者死亡,优于对照组;心脏毒性反应总发生率低于对照组,由于不良反应引起的剂量减低和周期延迟例数差异有统计学意义。结论:含PLD的化疗方案在老年初治淋巴瘤患者中的临床疗效确切,而骨髓毒性和心脏毒性低,安全性较好,老年患者有更好的依从性。

Objective:To explore the efficacy and safety of chemotherapy regimens containing doxorubicin liposomes for elderly patients with lymphoma.Methods:68 elderly patients over 65 years old with lymphoma were enrolled in the study,in which there 38 patients received chemotherapy regimen containing PLD,including diffuse large B cell lymphoma in 17 cases,follicular lymphoma in 7 cases,mantle cell lymphoma in 6 cases,T cell lymphoma in 5 cases,and other 3 cases.Results:Bone marrow toxicity is the most common adverse reaction,no patient died,and it is better than the control group.The total incidence of cardiac toxicity is lower than that of the control group.There is a significant difference in the dose reduction and the number of cycles delayed due to adverse reactions.Conclusion:The chemotherapy regimen containing PLD is effective in the treatment of elderly patients with lymphoma,but the toxicity of bone marrow and heart are low,and the safety is better.The elderly patients have better compliance.